Recently, a research paper titled "Effects of long-acting recombinant porcine FSH on reproductive performance and production efficiency of gilts and weaned sows" by the team of Professor Luo Haoshu, Founder and Chief Scientist of VJTBio, has been published in the internationally renowned academic journal Animal Reproduction Science. This study represents the first application of long-acting recombinant porcine follicle-stimulating hormone (rFSH) in batch production systems for pigs. The findings demonstrate that utilizing long-acting recombinant porcine FSH in combination with chorionic gonadotropin significantly enhances reproductive efficiency and production profitability in both gilts and multiparous sows, facilitating the high-quality development of China’s swine industry and the porcine reproduction sector. Batch production systems have been widely adopted by pig farming enterprises both domestically and internationally due to their effectiveness in enhancing production efficiency and economic returns. In batch production systems, equine chorionic gonadotropin (eCG, also referred to as PMSG) extracted from pregnant mare serum is conventionally used to synchronize estrus in swine herds. However, such extracted products present several drawbacks, including limited raw material sources, potential disease transmission risks, batch-to-batch inconsistency, and animal welfare concerns. Therefore, it is necessary to develop superior alternatives for sow reproduction management. This study utilized recombinant protein fusion technology and CHO cell expression platform to develop and produce recombinant fusion protein for practical use in swine reproduction. This study demonstrated through a series of sow experiments that the combination of rFSH and chorionic gonadotropin can effectively promote follicular development and estrus in sows. Comparative analysis with the extracted product eCG revealed that the group treated with rFSH in combination with chorionic gonadotropin yielded a higher total number of piglets in both gilts and multiparous sows.

The recombinant fusion protein developed in this study is expressed via secretion using CHO cells in vitro, thereby eliminating constraints related to raw material supply. Through rigorous quality control measures, issues such as batch-to-batch inconsistency and risks of disease transmission are effectively addressed. Moreover, as the entire production process is conducted in vitro, animal welfare concerns are fully mitigated. More importantly, this recombinant fusion protein exhibits high molecular biological activity and elevated protein expression levels, which contribute to reduced production costs and, consequently, lower end-user expenses.

The long-acting recombinant FSH fusion protein combined with chorionic gonadotropin facilitates follicular development and estrus in sows. With its distinct advantages in safety, quality, and cost-effectiveness, it effectively addresses the critical challenges associated with the use of extracted products in agriculture and has the potential to become an efficient and innovative solution for synchronizing estrus in swine herds.